Distribution of the components of the NCEP ATP III-defined metabolic syndrome in newly diagnosed diabetes and non-diabetes Caucasian subjects; implications for metabolic syndrome prevention and treatment

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 3, 2007, Pages 187-191

  Czupryniak, L ^a,b   Saryusz Wolska, M ^a   Pawowski, M ^a   Wojcik, J ^a   Loba, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Barlicki University Hospital ^*  (Poland)

Author keywords

Dyslipidemia; Hypertension; Insulin resistance; Metabolic syndrome; Obesity; Prevention

Indexed keywords

ANTIHYPERTENSIVE AGENT; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD PRESSURE; CHOLESTEROL, HDL; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLAND; PREVALENCE; TRIGLYCERIDES;

EID: 34247328907     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-956167     Document Type: Article

References (29)

1. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older. Diabetes 2003; 52: 1210-1214
2. Anderson JL, Horne BD, Jones HU, Reyna SP, Carlquist JF, Bair TL, Pearson RR, Lappe DL, Muhlestein JB, Intermountain Heart Collaboration (IHC) Study.: Which Features of the Metabolic Syndrome Predict the Prevalence and Clinical Outcomes of Angiographic Coronary Artery Disease? Cardiology 2004; 101: 185-193
3. Central Statistical Office, Poland. 2004; http://www.stat.gov.pl/english/ index.htm accessed 15 July 2006
4. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES: Relationship to Insulin Resistance of the Adult Treatment Panel III Diagnostic Criteria for Identification of the Metabolic Syndrome. Diabetes 2004; 53: 1195-1200
5. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910
6. Drzewoski J, Saryusz-Wolska M, Czupryniak L: Prevalence of type 2 diabetes mellitus and selected metabolic disorders in urban population aged >35 years. Pol Arch Med Wewn 2001; 106: 787-791
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
8. Ford ES, Giles WH, Dietz WH: Prevalence of the Metabolic Syndrome Among US Adults. Findings From the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359
9. Hanefeld M, Leonhardt W: Das Metabolische Syndrome. Dtsch Gesundheitsw 1981; 36: 545-551
10. Hanley AJG, Wagenknecht LE, D'Agostino Jr RB, Zinman B, Haffner SM: Identification of Subjects with Insulin Resistance and β-Cell Dysfunction Using Alternative Definitions of the Metabolic Syndrome. Diabetes 2003; 52: 2740-2747
11. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, DECODE Study Group: Prevalence of the Metabolic Syndrome and Its Relation to All-Cause and Cardiovascular Mortality in Nondiabetic European Men and Women. Arch Intern Med 2004; 164: 1066-1076
12. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689
13. Jacobson TA, Case CC, Roberts S, Buckley A, Murtaugh KM, Sung JCY, Gause D, Varas C, Ballantyne CM: Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obesity Metabol 2004; 6: 353-362
14. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men. JAMA 2002; 288: 2709-2716
15. Linnemann B, Voigt W, Nobel W, Janka HU: C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006; 114: 127-134
16. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM: The Metabolic Syndrome as Predictor of Type 2 Diabetes. The San Antonio Heart Study. Diabetes Care 2003; 26: 3153-3159
17. Matsuzawa Y: The metabolic syndrome and adipocytokines. FEBS Lett 2006; 580: 2917-2921
18. Meigs JB, Wilson PWF, Nathan DM, D'Agostino Sr RB, Williams K, Haffner SM: Prevalence and Characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003; 52: 2160-2167
19. Meigs JB: Insulin Resistance Syndrome? Syndrome X? Multiple Metabolic Syndrome? A Syndrome At All? Factor Analysis Reveals Patterns in the Fabric of Correlated Metabolic Risk Factors. Am J Epidemiol 2000; 152: 908-911
20. Mielck A, Reitmeir P, Rathmann W: Knowledge about diabetes and participation in diabetes training courses: the need for improving health care for diabetes patients with low SES. Exp Clin Endocrinol Diabetes 2006; 114: 240-248
21. Mori Y, Hoshino K, Yokota K, Yokose T, Tajima N: Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men. Exp Clin Endocrinol Diabetes 2005; 113: 334-339
22. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FLJ, SMART Study Group: The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004; 25: 342-348
23. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB: The Metabolic Syndrome. Prevalence and Associated Risk Factor Findings in the US Population From the Third National Health and Nutrition Examination Survey 1998-1994. Arch Intern Med 2003; 163: 427-436
24. Reaven GM: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1998; 37: 1595-1607
25. Stumvoll M, Gerich J: Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 diabetes. Clin Lab Med 2001; 21: 31-51
26. Szybinski Z: Polish Multicenter Study on Diabetes Epidemiology 1998-2000. Pol Arch Med Wewn 2001; 106: 751-758
27. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
28. Turner RC, Matthews DR, Holman RR, Peto J: Relative contributions of insulin deficiency and insulin resistance in maturity-onset diabetes. Lancet 1982; i: 596-598
29. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization, 1999